PanCAN and Seven Bridges will conduct collaborative analyses to accelerate the basic research and discovery phase of therapeutic development. Credit: Belova59 from Pixabay.

Patient advocacy organisation Pancreatic Cancer Action Network (PanCAN) has selected Seven Bridges to build a customised, integrated health data platform to accelerate research into pancreatic cancer.

Using the platform, researchers will get access to a range of longitudinal clinical, genetic and outcome data generated through PanCAN’s research and clinical initiatives.

They will also be able to conduct collaborative analyses to accelerate the basic research and discovery phase of therapeutic development.

This is expected to improve outcomes for pancreatic cancer patients.

Seven Bridges Public Programs director Jack DiGiovanna said: “Our company’s experience developing data analysis ecosystems gives us confidence in our ability to rapidly make this multi-omic clinical data available for researchers and provide the scientific and technical resources to make that data actionable.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

“Our partnership with PanCAN will deliver valuable insights, enabling further health improvements for all pancreatic cancer patients.”

PanCAN collects de-identified patient health data as part of its mission to accelerate progress and improve patient outcomes.

Data is collected through various tools and services including its Patient Registry, Know Your Tumor molecular profiling service and Precision Promise clinical trial programme.

PanCAN chief data officer Sudheer Doss said: “Open sharing of data and collaboration across the pancreatic cancer research community are the keys to moving the needle in our fight against the world’s toughest cancer.

“Through our partnership with Seven Bridges, we are building a platform that accelerates the sharing of de-identified data from our industry-leading programs in a secure, compliant and efficient manner.”

Seven Bridges chief scientific officer Brandi Davis-Dusenbery said that researchers can get accelerated access to these data and will be able to transform insights into action through the discovery of new treatments based on novel disease targets, biomarkers or molecular pathways.